PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3

Jorge A Benitez1, Jianhui Ma1, Matteo D'Antonio2,3

  • 1Ludwig Institute for Cancer Research, La Jolla, California 92093-0660, USA.

Insights

PTEN loss in glioblastoma involves a new chromatin role. Inhibiting DAXX, a protein interacting with PTEN, suppresses tumor growth by altering histone H3.3 distribution.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Glioblastoma (GBM) is an aggressive brain cancer with frequent PTEN tumor suppressor gene alterations.
  • PTEN loss is linked to therapeutic resistance and poor prognosis in GBM.
  • A novel chromatin-associated function of PTEN is investigated.

Purpose of the Study:

  • To elucidate the non-enzymatic, chromatin-associated function of PTEN.
  • To explore the interaction between PTEN, DAXX, and H3.3 in glioblastoma.
  • To evaluate DAXX inhibition as a therapeutic strategy for PTEN-deficient GBM.

Main Methods:

  • Co-immunoprecipitation to assess protein interactions.
  • Chromatin immunoprecipitation to analyze histone modifications and occupancy.
  • Orthotopic mouse xenograft models using human PTEN-deficient glioma cells.
  • Analysis of PTEN and DAXX expression in GBM patient samples.

Main Results:

  • PTEN interacts with the histone chaperone DAXX and modulates DAXX-H3.3 complex formation on chromatin.
  • PTEN regulates oncogene expression via DAXX-H3.3 interaction, independent of its phosphatase activity.
  • DAXX inhibition in mice with PTEN-deficient gliomas suppressed tumor growth and improved survival.
  • DAXX inhibition led to global H3.3 redistribution, upregulating tumor suppressors and downregulating oncogenes.
  • DAXX expression inversely correlates with PTEN expression in GBM patient tumors.

Conclusions:

  • PTEN functions in a novel chromatin complex with DAXX and H3.3 to regulate gene expression.
  • DAXX inhibition presents a targeted therapeutic strategy for PTEN-deficient glioblastomas.
  • This synthetic lethality approach offers a promising avenue for treating a subset of aggressive brain cancers.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
4.0K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K